Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Irving, G. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Irving, G. A.
NEUROLOGY 2005;64:S21-S27
© 2005 American Academy of Neurology

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Contemporary assessment and management of neuropathic pain

Gordon A. Irving, MD

From the University of Washington Medical School and the Swedish Pain Center, Seattle, Washington, USA.

Address correspondence to Dr. Gordon A. Irving, Swedish Pain Center, Suite 200, 1101 Madison St., Seattle, WA 98104, USA.

Preclinical studies have increased our understanding of the pathophysiology of neuropathic pain at the anatomic, cellular, and molecular levels. These lines of investigation have enabled more logical uses of older therapies for neuropathic pain and have contributed to our understanding of the potential mechanisms underlying the efficacy of newer remedies. The identification of receptor systems and the development of genetically modified animal models for the study of neuropathic pain have greatly increased our understanding of effective clinical treatments. This review focuses on the central and peripheral nervous system changes believed to be important in the initiation and perpetuation of neuropathic pain. Currently used medications, as well as medications that are on the horizon, are highlighted.


Publication of this supplement was made possible by an educational grant from GlaxoSmithKline. G.A.I. has disclosed no financial relationship with the sponsor.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
S. S. Negus, T. W. Vanderah, M. R. Brandt, E. J. Bilsky, L. Becerra, and D. Borsook
Preclinical Assessment of Candidate Analgesic Drugs: Recent Advances and Future Challenges
J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 507 - 514.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
I. Lalani
Emerging subspecialties in neurology: Pain medicine
Neurology, October 24, 2006; 67(8): 1522 - 1523.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.